Latest Breaking News On - Melyssa weible - Page 6 : vimarsana.com

Cingulate to Participate in Benzinga All Live Access Event

KANSAS CITY, Kan., April 14, 2023 (GLOBE NEWSWIRE) Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision.

United statesKansas cityThomas daltonShanej schafferMatt krepsMelyssa weibleBenzinga youtubeElixir health public relationsCingulate incDarrow associatesPrecision timed releaseBenzinga all accessTuesday aprilHyperactivity disorderPublic relations

Impel NeuroPharma Inc (IMPL) Appoints Darren Cline to its Board

Impel NeuroPharma Inc (IMPL) Appoints Darren Cline to its Board
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Melyssa weibleAdrian adamsJanhavi mohiteDarren clineH stewart parkerElixir health public relationsImpel pharmaceuticals incExchange commissionJazz pharmaceuticalsGw pharmaceuticalsImpel leadership teamMenarini groupImpel pharmaceuticalsImpel boardChief executive officerEpygenix therapeutics

Impel Pharmaceuticals to Present Data on Trudhesa® Nasal Spray for Treatment of Acute Migraine at 2023 American Academy of Neurology Annual Meeting

Highlights Include Multiple Presentations Addressing Safety and Efficacy of TrudhesaSEATTLE, April 11, 2023 Impel Pharmaceuticals , a commercial-stage pharmaceutical company developing. | April 11, 2023

United statesMelyssa weibleJennifer robbleeZubair ahmedAlexander feoktistovSutapa rayElixir health public relationsImpel pharmaceuticalsAmerican academy of neurologySynergy integrative headache centerBarrow neurological instituteImpel pharmaceuticals incExchange commissionSectional survey of prevailing opinionsAmerican academyAnnual meeting

Impel Pharmaceuticals Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Trudhesa® Achieved nTRx of Over 58.4K in 2022; nTRx Increased by 19.4% in Q4 vs. Q3 2022 Net Product Revenue Finished Year at $12.7 Million; Increased 62% in Q4 vs. Q3 2022 to $5 Million Impel. | March 24, 2023

United statesMelyssa weibleAdrian adamsDecember trudhesaJanhavi mohiteDrug administrationAmerican headache societyExchange commissionImpel pharmaceuticals incAmerican academy of neurologyDevelopment rd expensesElixir health public relationsImpel pharmaceuticalsProduct revenue finished yearHost investor conference call todayChief executive officer

Impel Pharmaceuticals Announces Strategic Repriortization, Continues Focus on Maximizing Trudhesa® Commercial Opportunity

Impel Pharmaceuticals Announces Strategic Repriortization, Continues Focus on Maximizing Trudhesa® Commercial Opportunity
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Adrian adamsStephen shrewsburyChristina tartagliaMelyssa weibleExchange commissionImpel pharmaceuticalsExpansion of salesImpel pharmaceuticals incElixir health public relationsSaving measures eliminate pipeline programsReduce headcountDrive trudhesa growth viaBased sales representativesGrowth momentum continuesNew prescriptionsChief executive officer